Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer
- 30 September 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 15 (11) , 1427-1440
Abstract
(2015). Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. Expert Review of Molecular Diagnostics: Vol. 15, No. 11, pp. 1427-1440.Keywords
This publication has 100 references indexed in Scilit:
- Changes in Electric Properties of Human Breast Cancer CellsThe Journal of Membrane Biology, 2012
- EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospectsCancer Treatment Reviews, 2012
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and ErlotinibClinical Cancer Research, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsLung Cancer, 2011
- Saliva: diagnostics and therapeutic perspectivesOral Diseases, 2010
- Isolation of circulating tumor cells using a microvortex-generating herringbone-chipProceedings of the National Academy of Sciences, 2010
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsNew England Journal of Medicine, 2008